Grants for Pharmaceutical and Biotech Companies in Belgium

Belgium consistently ranks among the top five biotech ecosystems in Europe. The country hosts major global pharma players alongside hundreds of innovative SMEs and spin-offs from universities like KU Leuven, UGent, UCLouvain, and VUB.

Public funding for life sciences research is substantial at every level — regional, federal, and European. Companies that understand the full landscape can stack multiple programs and significantly reduce their R&D cost base.

The challenge is that funding bodies are fragmented across regions, and pharma companies often operate across Flanders and Brussels simultaneously. Knowing which agency to approach first is itself a strategic decision.

VLAIO, the Flanders Innovation and Entrepreneurship agency, offers direct subsidies under its O&O (Research and Development) program. These grants can cover 25–50% of eligible R&D costs for companies carrying out industrial research or experimental development.

Pharmaceutical companies developing new compounds, drug delivery systems, diagnostics, or manufacturing processes can qualify. The application requires a clear technical description, a budget breakdown, and evidence of innovation over existing solutions.

VLAIO also runs collaborative R&D programs through imec, VIB, and Flanders Bio — the main life sciences cluster. Consortium grants involving at least one research partner typically receive higher subsidy rates.

Visit BelGrant's R&D grants overview to compare VLAIO O&O with other available R&D funding in Belgium.

Innoviris, the Brussels innovation agency, runs several programs relevant to biotech and medtech companies based in the Brussels-Capital Region. The Explore program supports fundamental and industrial research, while Bridge funds applied collaborative projects.

Innoviris also manages Co-Create for ecosystem-building projects and has historically supported life sciences scale-ups through its Spin-off and Spin-out programs. Brussels-based biotech companies benefit from access to both French-speaking and Dutch-speaking networks.

Innoviris grants are reserved for companies with an operational presence in Brussels. Companies with headquarters elsewhere but a Brussels office may still qualify, depending on where the R&D activity takes place.

Belgium's federal R&D tax framework is one of the most competitive in Europe. The partial exemption from withholding tax on wages for qualified researchers allows companies to retain up to 80% of payroll taxes for R&D staff.

The innovation income deduction (IID) allows companies to deduct 85% of qualifying patent income from their taxable base, resulting in an effective tax rate close to 3.75% on IP revenues. Biotech companies building patent portfolios should model this benefit from early stages.

Investment deductions for R&D equipment and the R&D tax credit round out the federal incentive stack. Unlike regional grants, these benefits do not require advance applications — they are claimed in the annual corporate tax return.

Horizon Europe's Cluster 1 (Health) funds projects in areas such as cancer, infectious diseases, rare diseases, cardiovascular health, neuroscience, and digital health. Belgian biotech companies frequently participate as project coordinators or consortium partners.

The EIC Pathfinder is specifically designed for early-stage deep tech projects with transformative potential, including novel biotech platforms, cell and gene therapies, and AI-driven drug discovery. Both grant and blended finance (grant + equity) options are available.

The EIC Accelerator is the natural next step for biotech scale-ups seeking larger non-dilutive grants (up to €2.5M) combined with EIC Fund equity investment. Belgian biotech companies have a solid track record in EIC calls.

Explore the full range of innovation grants available in Belgium to see where EU programs fit alongside regional and federal support.

Most Belgian pharma and biotech grants require that the company be registered in Belgium (or the relevant region), carry out the R&D activity domestically, and demonstrate genuine innovation rather than routine development.

Company size matters. SMEs receive higher subsidy rates under VLAIO and Innoviris. Larger pharma companies may access fewer direct grants but can still benefit substantially from federal tax incentives and EU programs.

The strongest applications combine a compelling scientific narrative with a clear commercial pathway. Generic descriptions of drug development rarely succeed — reviewers reward specificity about the mechanism, target indication, and competitive differentiation.

Ready to identify the right grants for your pharma or biotech company? Ask Lucas, BelGrant's AI grant assistant, for a personalised funding map based on your company profile, region, and R&D stage.